top of page

Astellas Gene Therapies

     Drug: AT466

     Approach: AAV-antisense

     Status: Preclinical.  

     Company website explaining AT466.

     April 8, 2019 Press Release announcing collaboration with Nationwide Children's Hospital

    Dec. 2021 Press Release announcing collaboration with Dyno for viral vector delivery technology.

     

bottom of page